Ozempic and Wegovy: can you use them interchangeably?

The myth worth correcting first: same drug does not mean same licence

The widespread assumption is that because Ozempic and Wegovy share a molecule, they are medically equivalent options you can pick between like two flavours of the same thing. They are not. The NHS patient page on semaglutide is explicit: Ozempic's UK licence covers blood sugar control in type 2 diabetes, while Wegovy's licence covers weight management. The MHRA has also stated publicly that GLP-1 medicines are not assessed for quick or cosmetic weight loss, and that prescribing decisions must reflect the approved indication.

What does that mean practically? A GP or independent prescriber who writes Ozempic for weight loss in a patient without type 2 diabetes is prescribing off-label. That is sometimes clinically appropriate, but it is not the same as prescribing a medicine within its licensed purpose, and it carries different obligations for the prescriber. It also means any clinical monitoring, dose escalation schedule and stopping criteria designed for the weight-loss indication don't automatically apply.

The dose ranges make this concrete. Ozempic tops out at 2mg weekly; Wegovy's maintenance dose sits at 2.4mg, with the MHRA having approved a 7.2mg single-dose pen in April 2026 for adults with obesity. Those aren't the same treatment pathway, even if the molecule is identical.

What the licensed route for weight loss actually looks like

For weight management, the medicines licensed in the UK are Wegovy (semaglutide) and Mounjaro (tirzepatide). Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure or high cholesterol. Mounjaro holds the same broad eligibility profile and is the only dual GIP and GLP-1 receptor agonist licensed here. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

NICE's appraisal of semaglutide for weight management, TA875, recommends Wegovy within specialist weight management services, for a maximum of two years, alongside multidisciplinary support. That's the NHS pathway. Private prescribing through a regulated online pharmacy follows the same licensed eligibility criteria, without the waiting list or specialist-referral requirement.

Ozempic doesn't feature in that pathway at all. If you've been using Ozempic for type 2 diabetes and are now curious about what a dedicated weight-loss treatment might look like, that's a different conversation, and one worth having with a prescriber who can review your full picture. The question of moving from Ozempic to Wegovy involves your diabetes management, your current doses, and timing, none of which can be resolved by a product comparison page.

The real risk in treating these as interchangeable

Beyond the licensing point, treating Ozempic and Wegovy as swap-in alternatives creates practical risks. Dose schedules differ. The titration steps for Wegovy's weight-management licence are designed to reach a maintenance dose of 2.4mg (or higher under the newer 7.2mg pathway) in a structured way, starting at 0.25mg and stepping up roughly every four weeks under prescriber oversight. Someone sourcing Ozempic pens without clinical supervision for weight-loss purposes may not be following any equivalent structure.

There's also the supply-chain question. The MHRA has warned about counterfeit semaglutide pens sold online, some of which have contained insulin rather than the labelled medicine. Sellers offering either product without a prescription, or through social media channels, are a serious red flag, report them via the MHRA's Yellow Card service. Any legitimate UK pharmacy can be verified on the GPhC register; our own registration number (9012878) is publicly searchable there.

If you're weighing up your options and want to understand whether Wegovy or Mounjaro might be appropriate for you, the starting point is a clinical consultation. You can check your eligibility and start a free consultation with our prescribers, who review every case personally. There's also a broader look at what weight-loss treatment involves on our weight-loss overview page, if you'd like context before deciding anything.

If you're already on Ozempic for diabetes and want to understand your options

This is a genuinely common situation, and it deserves a straight answer. Ozempic is managing a medical condition. Changing to a weight-management medicine, or adding one, is not a straightforward product switch, it involves your HbA1c, your diabetes team, and your current prescriber. The clinical considerations around changing from Ozempic to Wegovy are more involved than a label comparison suggests.

What some people in this situation find useful is understanding the semaglutide landscape more fully, how Wegovy relates to Ozempic as products, what the licensed weight-management dose actually does, and what private treatment involves. Our FAQs address several of the practical questions that follow. If you're not sure what route fits your circumstances, reaching out via our support team is a reasonable first step before committing to anything. And for a full overview of how semaglutide works across its different forms, our Ozempic and semaglutide overview covers the ground clearly.